Vertex Pharmaceuticals: A $5B+ Opportunity in Pain and Kidney Disease Treatments?
Vertex Pharmaceuticals: Jefferies upgrades to “Buy” with $550 price target, citing $5B+ potential in pain and kidney disease treatments. Promising pipeline and strong cystic fibrosis business position Vertex for significant growth.
Vertex Pharmaceuticals: A $5B+ Opportunity in Pain and Kidney Disease Treatments? Read More »